Table 2 Results of systematic review with cohort studies of COVID-19 patients—chest CT
From: Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis
Author | Follow-up timing of latest tests | Cohort Size, N | Residual CT abnormalities % (N) | Parenchymal band or fibrous stripe % (N) | GGO % (N) | Consolidation % (N) | Interstitial thickening or interlobular septal thickening % (N) | Bronchovascular bundle distortion or bronchiectasis % (N) | Thickening of adjacent pleura % (N) | Pleural effusion % (N) | Crazy paving % (N) |
|---|---|---|---|---|---|---|---|---|---|---|---|
You [17] | PFT Non-severe cases: 40 ± 11.6 days Severe cases: 34.7 ± 16.5 days CT was taken closest to the date of PFT | 18 | 83% (15) | NA | 61.1% (11) | NA | NA | NA | NA | NA | NA |
Huang [18] | 30Â days after discharge | 57 | 54.4% (31) | NA | NA | NA | NA | NA | NA | NA | NA |
Liu [19] | 31 (20–37) days after discharge | 51 | 35.3% (18) | NA | 33.3% (17) | 2.0% (1) | 35.3% (18) | 3.9% (2) | 23.5% (12) | NA | NA |
Zhao [20] | 64–93 days after discharge | 55 | 70.9% (39) | NA | 12.7% (7) | NA | 27.3% (15) | NA | 41.8% (23) | 1.8% (1) | 5.5% (3) |
Zhong [21] | 39.6 ± 6.0 days after symptom onset 19.7 ± 4.1 days after discharge | 52 | 69.2% (36) | 36.5% (19) | 63.5% (33) | 9.6% (5) | 5.8% (3) | 7.7% (4) | NA | NA | NA |
Liang [22] | 3Â months after discharge | 21 | 23.8% (5) | NA | 23.8% (5) | NA | NA | NA | NA | NA | NA |
Tabatabaei [23] | 91 ± 15.5 days after initial CT | 52 | 42.3% (22) | 19.2% (10) | 36.5% (19) | NA | NA | NA | NA | NA | NA |
van den Borst [24] | 13.0 ± 2.2 weeks after symptom onset 9.1 ± 1.6 weeks after discharge | 84 | 90.5% (76) | 64.3% (54) | 86.9% (73) | NA | NA | 60.7% (51) | NA | NA | NA |
Smet [25] | 74 ± 12 days after diagnosis | 220 | 26.4% (58) | NA | 25.0% (55) | 3.6% (8) | NA | NA | NA | NA | 40.9% (90) |
Lerum [27] | 83 [73, 90] days after hospital admission | 103 | NA | 18.4% (19) | 23.3% (24) | NA | NA | NA | NA | NA | NA |
Huang [29] | 186 [175, 199] days after symptom onset | 353 | 52.7% (186) | 15.9% (56) | 44.8% (158) | 1.1% (4) | 0.8% (3) | NA | 4.2% (15) | NA | NA |
Guler [30] | 128 [108, 144] days after symptom onset | 52 | NA | 51.9% (27) | 57.7%(30) | 28.8% (15) | 1.9% (1) | 38.5% (20) | 1.9% (1) | NA | NA |
Han [31] | 175 ± 20 days after symptom onset | 114 | 62.3% (71) | NA | 62.3% (71) | 23.7% (27) | NA | 10.5% (12) | 35.1% (40) | 8.8% (10) | NA |